RAPT Therapeutics, Inc. (RAPT)
Mar 3, 2026 - RAPT was delisted (reason: acquired by GSK)
58.02
0.00 (0.00%)
Inactive · Last trade price on Mar 2, 2026

RAPT Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,7942098556781,086489
Market Cap Growth
1042.12%-75.60%26.03%-37.52%121.87%-18.83%
Enterprise Value
1,639-17.99702.84438.16895.91377.76
Last Close Price
58.0212.64198.80158.40293.84158.00
PE Ratio
--0.50-8.15-7.67-14.52-9.02
PS Ratio
---444.16284.7097.04
PB Ratio
6.431.105.812.775.824.70
P/TBV Ratio
8.270.346.482.635.404.58
P/FCF Ratio
--2.50-8.71-9.47-17.57-11.97
P/OCF Ratio
--2.50-8.81-9.58-17.79-12.08
EV/Sales Ratio
---286.94234.9674.92
EV/EBITDA Ratio
-0.13-5.58-5.17-13.13-7.25
EV/EBIT Ratio
-0.13-5.53-5.11-12.94-7.10
EV/FCF Ratio
-0.22-7.16-6.12-14.50-9.24
Debt / Equity Ratio
0.020.020.050.0400
Debt / EBITDA Ratio
-0.02-0.03-0.05-0.11--
Debt / FCF Ratio
-0.03-0.05-0.07-0.13--
Net Debt / Equity Ratio
-1.02-1.19-1.03-0.98-1.02-1.07
Net Debt / EBITDA Ratio
1.391.681.212.832.782.14
Net Debt / FCF Ratio
1.792.721.553.353.072.73
Asset Turnover
-000.010.020.05
Quick Ratio
11.764.787.2817.5119.779.50
Current Ratio
12.044.877.4117.7720.119.84
Return on Equity (ROE)
-61.80%-77.09%-59.56%-38.85%-47.64%-59.66%
Return on Assets (ROA)
-55.48%-65.80%-57.82%-36.91%-43.58%-53.28%
Return on Invested Capital (ROIC)
5218.25%4243.87%-82507.79%-2970.23%-17345.61%-4211.96%
Return on Capital Employed (ROCE)
-65.42%-79.25%-62.98%-38.91%-46.72%-58.29%
Earnings Yield
-5.89%-201.90%-12.27%-13.03%-6.89%-11.09%
FCF Yield
-4.83%-40.00%-11.48%-10.56%-5.69%-8.36%
Buyback Yield / Dilution
-0.06%-73.29%-0.17%-19.34%-13.03%-15.42%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q